



Predictive and Prognostic Factors in Mesothelioma

Guest Editors:

Dr. Federica Grosso

Mesothelioma Unit, Azienda
Ospedaliera SS Antonio e Biagio
e Cesare Arrigo, 15121
Alessandria, Italy

**Dr. Alessandra Curioni-
Fontecedro**

Department of Medical Oncology
and Hematology, University
Hospital Zurich, 8091 Zurich,
Switzerland

Dr. Stefanie Hiltbrunner

Department of Medical Oncology
and Hematology, University
Hospital Zurich, Rämistrasse 100,
8091 Zurich, Switzerland

Deadline for manuscript
submissions:

closed (20 April 2023)

Message from the Guest Editors

Dear Colleagues,

Malignant pleural mesothelioma is an aggressive disease with poor prognosis. Recently the use of immunotherapy in first line with Nivolumab and Ipilimumab have improved the overall survival of patients with inoperable disease compared to chemotherapy. To date, it is unclear which factors might play a role in prediction of therapy-responses and prognosis for this disease.

This special issue will cover a broad range of data regarding the predictive and prognostic role of:

- Clinical features
- Laboratory values
- Imaging features
- Molecular signatures
- Tumor microenvironment characteristics

Dr. Federica Grosso

Dr. Alessandra Curioni-Fontecedro

Dr. Stefanie Hiltbrunner

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)